Avenue Therapeutics Stock Price, News & Analysis (NASDAQ:ATXI)

$3.80 -0.05 (-1.30 %)
(As of 01/23/2018 12:39 PM ET)
Previous Close$3.85
Today's Range$3.66 - $4.24
52-Week Range$3.40 - $8.58
Volume49,300 shs
Average Volume26,407 shs
Market Capitalization$39.52 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Avenue Therapeutics (NASDAQ:ATXI)

Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.

Receive ATXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATXI
CUSIPN/A
Phone781-652-4500

Debt

Debt-to-Equity RatioN/A
Current Ratio13.15%
Quick Ratio13.15%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees3
Outstanding Shares10,270,000

Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics Inc (NASDAQ:ATXI) issued its quarterly earnings results on Thursday, November, 9th. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.05. View Avenue Therapeutics' Earnings History.

Who are some of Avenue Therapeutics' key competitors?

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

When did Avenue Therapeutics' lock-up period expire?

Avenue Therapeutics' lock-up period expired on Monday, December 25th. Avenue Therapeutics had issued 5,500,000 shares in its IPO on June 27th. The total size of the offering was $33,000,000 based on an initial share price of $6.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

How do I buy Avenue Therapeutics stock?

Shares of Avenue Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avenue Therapeutics' stock price today?

One share of Avenue Therapeutics stock can currently be purchased for approximately $3.80.

How big of a company is Avenue Therapeutics?

Avenue Therapeutics has a market capitalization of $39.52 million. Avenue Therapeutics employs 3 workers across the globe.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Avenue Therapeutics (ATXI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  115
MarketBeat's community ratings are surveys of what our community members think about Avenue Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Avenue Therapeutics (NASDAQ:ATXI) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Avenue Therapeutics (NASDAQ:ATXI) Earnings History and Estimates Chart

Earnings by Quarter for Avenue Therapeutics (NASDAQ:ATXI)

Avenue Therapeutics (NASDAQ ATXI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.25)($0.30)ViewN/AView Earnings Details
8/11/2017Q2 2017($0.54)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Avenue Therapeutics (NASDAQ:ATXI) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Avenue Therapeutics (NASDAQ:ATXI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Avenue Therapeutics (NASDAQ ATXI) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 1.36%
Insider Trades by Quarter for Avenue Therapeutics (NASDAQ:ATXI)

Avenue Therapeutics (NASDAQ ATXI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/17/2017Neil HerskowitzDirectorBuy1,000$5.01$5,010.00View SEC Filing  
10/9/2017Neil HerskowitzDirectorBuy500$5.24$2,620.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Avenue Therapeutics (NASDAQ ATXI) News Headlines

Source:

SEC Filings

Avenue Therapeutics (NASDAQ:ATXI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Avenue Therapeutics (NASDAQ:ATXI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Avenue Therapeutics (NASDAQ ATXI) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.